vs
ASURE SOFTWARE INC（ASUR）与Day One Biopharmaceuticals, Inc.（DAWN）财务数据对比。点击上方公司名可切换其他公司
Day One Biopharmaceuticals, Inc.的季度营收约是ASURE SOFTWARE INC的1.1倍（$39.8M vs $36.3M），ASURE SOFTWARE INC净利率更高（-14.8% vs -49.6%，领先34.8%），ASURE SOFTWARE INC同比增速更快（23.7% vs -57.6%）
Asure Software是一家软件企业，其前身为Forgent Networks，2007年9月完成品牌更名后，业务逐渐拓展至人力资本管理领域，为客户提供薪资发放、考勤管理、人才管理、人力资源管理、福利管理以及保险相关服务等解决方案。
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
ASUR vs DAWN — 直观对比
营收规模更大
DAWN
是对方的1.1倍
$36.3M
营收增速更快
ASUR
高出81.3%
-57.6%
净利率更高
ASUR
高出34.8%
-49.6%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $36.3M | $39.8M |
| 净利润 | $-5.4M | $-19.7M |
| 毛利率 | 63.8% | — |
| 营业利润率 | -9.7% | -60.9% |
| 净利率 | -14.8% | -49.6% |
| 营收同比 | 23.7% | -57.6% |
| 净利润同比 | -37.5% | -153.3% |
| 每股收益（稀释后） | $-0.19 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASURDAWN
| Q3 25 | $36.3M | $39.8M | ||
| Q2 25 | $30.1M | $33.9M | ||
| Q1 25 | $34.9M | $30.8M | ||
| Q3 24 | $29.3M | $93.8M | ||
| Q2 24 | $28.0M | — | ||
| Q1 24 | $31.7M | $0 | ||
| Q4 23 | $26.3M | — | ||
| Q3 23 | $29.3M | $0 |
净利润ASURDAWN
| Q3 25 | $-5.4M | $-19.7M | ||
| Q2 25 | $-6.1M | $-30.3M | ||
| Q1 25 | $-2.4M | $-36.0M | ||
| Q3 24 | $-3.9M | $37.0M | ||
| Q2 24 | $-4.4M | — | ||
| Q1 24 | $-308.0K | $-62.4M | ||
| Q4 23 | $-3.6M | — | ||
| Q3 23 | $-2.2M | $-46.1M |
毛利率ASURDAWN
| Q3 25 | 63.8% | — | ||
| Q2 25 | 66.1% | — | ||
| Q1 25 | 70.6% | — | ||
| Q3 24 | 67.2% | — | ||
| Q2 24 | 67.3% | — | ||
| Q1 24 | 71.4% | — | ||
| Q4 23 | 67.9% | — | ||
| Q3 23 | 72.5% | — |
营业利润率ASURDAWN
| Q3 25 | -9.7% | -60.9% | ||
| Q2 25 | -15.4% | -103.1% | ||
| Q1 25 | -5.8% | -133.5% | ||
| Q3 24 | -12.4% | 31.6% | ||
| Q2 24 | -14.9% | — | ||
| Q1 24 | -1.4% | — | ||
| Q4 23 | -14.3% | — | ||
| Q3 23 | 0.9% | — |
净利率ASURDAWN
| Q3 25 | -14.8% | -49.6% | ||
| Q2 25 | -20.3% | -89.4% | ||
| Q1 25 | -6.9% | -117.0% | ||
| Q3 24 | -13.3% | 39.5% | ||
| Q2 24 | -15.5% | — | ||
| Q1 24 | -1.0% | — | ||
| Q4 23 | -13.6% | — | ||
| Q3 23 | -7.5% | — |
每股收益（稀释后）ASURDAWN
| Q3 25 | $-0.19 | $-0.19 | ||
| Q2 25 | $-0.22 | $-0.29 | ||
| Q1 25 | $-0.09 | $-0.35 | ||
| Q3 24 | $-0.15 | $0.38 | ||
| Q2 24 | $-0.17 | — | ||
| Q1 24 | $-0.01 | $-0.72 | ||
| Q4 23 | $-0.16 | — | ||
| Q3 23 | $-0.10 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.5M | $451.6M |
| 总债务越低越好 | $70.4M | — |
| 股东权益账面价值 | $193.1M | $450.9M |
| 总资产 | $447.1M | $513.8M |
| 负债/权益比越低杠杆越低 | 0.36× | — |
8季度趋势，按日历期对齐
现金及短期投资ASURDAWN
| Q3 25 | $21.5M | $451.6M | ||
| Q2 25 | $66.0M | $453.1M | ||
| Q1 25 | $14.1M | $473.0M | ||
| Q3 24 | $11.2M | $558.4M | ||
| Q2 24 | $20.7M | — | ||
| Q1 24 | $23.2M | $317.9M | ||
| Q4 23 | $30.3M | — | ||
| Q3 23 | $32.8M | $405.5M |
总债务ASURDAWN
| Q3 25 | $70.4M | — | ||
| Q2 25 | $67.4M | — | ||
| Q1 25 | $14.1M | — | ||
| Q3 24 | $7.5M | — | ||
| Q2 24 | $6.0M | — | ||
| Q1 24 | $5.3M | — | ||
| Q4 23 | $4.3M | — | ||
| Q3 23 | $2.8M | — |
股东权益ASURDAWN
| Q3 25 | $193.1M | $450.9M | ||
| Q2 25 | $194.3M | $460.8M | ||
| Q1 25 | $197.7M | $479.5M | ||
| Q3 24 | $199.2M | $555.5M | ||
| Q2 24 | $195.5M | — | ||
| Q1 24 | $197.7M | $296.8M | ||
| Q4 23 | $191.7M | — | ||
| Q3 23 | $191.7M | $389.6M |
总资产ASURDAWN
| Q3 25 | $447.1M | $513.8M | ||
| Q2 25 | $505.6M | $519.0M | ||
| Q1 25 | $498.9M | $534.4M | ||
| Q3 24 | $428.1M | $600.8M | ||
| Q2 24 | $420.1M | — | ||
| Q1 24 | $469.3M | $326.6M | ||
| Q4 23 | $443.9M | — | ||
| Q3 23 | $394.5M | $414.2M |
负债/权益比ASURDAWN
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.07× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.03× | — | ||
| Q4 23 | 0.02× | — | ||
| Q3 23 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.8M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $5.7M | — |
| 自由现金流率自由现金流/营收 | 15.6% | — |
| 资本支出强度资本支出/营收 | 0.3% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $11.6M | — |
8季度趋势，按日历期对齐
经营现金流ASURDAWN
| Q3 25 | $5.8M | $-5.8M | ||
| Q2 25 | $3.2M | $-24.8M | ||
| Q1 25 | $2.0M | $-59.0M | ||
| Q3 24 | $1.3M | $50.8M | ||
| Q2 24 | $2.2M | — | ||
| Q1 24 | $-3.9M | $-49.7M | ||
| Q4 23 | $7.1M | — | ||
| Q3 23 | $5.7M | $-37.1M |
自由现金流ASURDAWN
| Q3 25 | $5.7M | — | ||
| Q2 25 | $3.0M | $-24.8M | ||
| Q1 25 | $1.8M | $-59.3M | ||
| Q3 24 | $1.2M | $50.0M | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | $-4.2M | — | ||
| Q4 23 | $6.8M | — | ||
| Q3 23 | $5.4M | $-37.1M |
自由现金流率ASURDAWN
| Q3 25 | 15.6% | — | ||
| Q2 25 | 9.8% | -73.2% | ||
| Q1 25 | 5.2% | -192.8% | ||
| Q3 24 | 3.9% | 53.4% | ||
| Q2 24 | 7.5% | — | ||
| Q1 24 | -13.2% | — | ||
| Q4 23 | 26.1% | — | ||
| Q3 23 | 18.4% | — |
资本支出强度ASURDAWN
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 0.7% | 0.0% | ||
| Q1 25 | 0.6% | 1.0% | ||
| Q3 24 | 0.6% | 0.8% | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.8% | — | ||
| Q4 23 | 0.8% | — | ||
| Q3 23 | 1.2% | — |
现金转化率ASURDAWN
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASUR
| Recurring | $31.8M | 88% |
| Lathem Time | $4.6M | 13% |
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
